Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immunogenicity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,146 result(s) found for: Immunogenicity. Displaying page 1 of 158.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-001512-28 Sponsor Protocol Number: COVIM Start Date*: 2021-05-11
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Immunogenicity of COVID-19 vaccines in medical staff and special risk populations
    Medical condition: SARS-CoV-2 immunogenicity
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000253-29 Sponsor Protocol Number: IC51-303 Start Date*: 2005-08-01
    Sponsor Name:Intercell AG
    Full Title: LONG TERM IMMUNOGENICITY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (JE-PIV). AN UNCONTROLLED PHASE 3 FOLLOW-UP STUDY
    Medical condition: Japanese encephalitis. This study is a follow-up to the pivotal immunogenicity and safety studies IC51-301 and IC51-302.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004122-70 Sponsor Protocol Number: 04M107 Start Date*: 2005-11-15
    Sponsor Name:Great Ormond Street Hospital
    Full Title: Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine.
    Medical condition: Ataxia Telangiectasia (AT) is a genetic condition in which there is a deficiency of the immune system with excessive susceptibility to pneumonia and other infections.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001714-26 Sponsor Protocol Number: CYD29 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly with Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003339-22 Sponsor Protocol Number: V70P2E1 Start Date*: 2007-10-11
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase II, Observer-Blind, Parallel Groups, Single-Center, Extension Study to Evaluate the Immunogenicity and Safety Following a Single Intramuscular Dose of FLUAD or Vaxigrip Influenza Vaccines i...
    Medical condition: Influenza
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2018-000211-25 Sponsor Protocol Number: MV-CHIK-205 Start Date*: 2018-07-27
    Sponsor Name:Themis Bioscience GmbH
    Full Title: Observer blinded, randomised study to investigate safety, tolerability and long-term immunogenicity of different dose regimens and formulations of MV-CHIK in healthy volunteers
    Medical condition: The study is being conducted in healthy volunteers for the prophylaxis of chikungunya virus (CHIKV) infection.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001228-32 Sponsor Protocol Number: COV002 Start Date*: 2020-05-04
    Sponsor Name:CTRG
    Full Title: A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19
    Medical condition: SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-015175-27 Sponsor Protocol Number: NVI-250 Start Date*: 2010-02-16
    Sponsor Name:Netherlands Vaccine Institute
    Full Title: Immunogenicity and safety of intradermal injection of reduced dose Inactivated Poliovirus vaccine (IPV) with a jet injector in healthy adults
    Medical condition: The vaccine in this healthy volunteer trial is indicated to prevent poliomyelitis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005183-42 Sponsor Protocol Number: IPV25 Start Date*: 2015-11-17
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Fractional Doses of Sanofi Pasteur’s Inactivated Poliomyelitis Vaccine (IMOVAX Polio™) Administered Intradermally versus Full Doses of Inactivated Poliomyelitis Vaccine...
    Medical condition: Poliomyelitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2024-000001-33 Sponsor Protocol Number: C4591048 Start Date*: 2024-02-07
    Sponsor Name:BioNTech SE
    Full Title: A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of Variant-Adapted BNT162b2 RNA-Based Vaccine Candidate(s) in Healthy Children
    Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    23.0 10021881 - Infections and infestations 10084510 Coronavirus infections HLT
    23.1 10021881 - Infections and infestations 10084529 2019 novel coronavirus infection LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004605-33 Sponsor Protocol Number: V59P14 Start Date*: 2014-11-17
    Sponsor Name:Novartis Vaccines & Diagnostics, Inc.
    Full Title: A Phase 3, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine When Administered with Routine Infan...
    Medical condition: Meningococcal disease causes high rates of morbidity and mortality even among patients who receive early antibiotic treatment.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005192-24 Sponsor Protocol Number: HAF65 Start Date*: 2015-11-19
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly with TRIMOVAX™ in 12-13 Months old Healthy Hepatitis A Seronegative Turkish Children
    Medical condition: Measles Mumps Rubella Hepatitis A
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002720-91 Sponsor Protocol Number: HBnr02 Start Date*: 2017-09-21
    Sponsor Name:CyTuVax BV
    Full Title: Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders.
    Medical condition: In a minority of the population (5-10%) standard vaccines against Hepatitis-B do not induce protective immunity, even after prolonged and repeated vaccination courses. Non- responsiveness to hepati...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003210-27 Sponsor Protocol Number: 201663 Start Date*: 2017-07-20
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIA, randomized, single-blind, multi-centric study to evaluate the immunogenicity, reactogenicity and safety of three doses of Pediarix, Hiberix and Prevenar 13 when co-administered with t...
    Medical condition: PCV-free HRV vaccine is indicated to prevent gastroenteritis (GE) caused by rotavirus (RV)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-002785-13 Sponsor Protocol Number: V130_10 Start Date*: 2020-12-04
    Sponsor Name:Seqirus Inc.
    Full Title: A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) and a United State...
    Medical condition: Prophylaxis of Influenza Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-006754-31 Sponsor Protocol Number: 80101 Start Date*: 2022-03-22
    Sponsor Name:Leiden University Medical Center
    Full Title: Establishing immunogenicity and safety of needle-free intradermal delivery by nanoporous ceramic skin patch of mRNA SARS-CoV-2 vaccine as a revaccination strategy in healthy volunteers
    Medical condition: Safety and immunogenicity after revaccination with Spikevax in healthy adults who have received Comirnaty as a primary vaccine
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001743-66 Sponsor Protocol Number: LSA3_1_06 Start Date*: 2007-09-20
    Sponsor Name:INSTITUT PASTEUR, Biomedical Parasitology Unit
    Full Title: Phase I and IIa trial to assess the safety, immunogenicity and protective efficacy against sporozoite challenge of the candidate malaria vaccine pfLSA-3 vaccine.
    Medical condition: P. falciparum infection (malaria)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005184-16 Sponsor Protocol Number: IPV26 Start Date*: 2015-11-17
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Fractional Booster Dose of sanofi pasteur’s Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intradermally versus Full Booster Dose of Inactivated Poliomye...
    Medical condition: Poliomyelitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-012385-31 Sponsor Protocol Number: V87_17 Start Date*: 2009-09-01
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase II, Randomized, Controlled, Double-blind, Multi-center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adj...
    Medical condition: Avian influenza
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-001952-35 Sponsor Protocol Number: M71P1 Start Date*: 2005-09-15
    Sponsor Name:Chiron S.r.l.
    Full Title: A Phase IV, Observer-Blind, Randomized, Parallel Groups, Single-Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of Two 0.25 mL Intramuscular Doses of Agrippal™ S1, Infl...
    Medical condition: Influenza
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 06 15:29:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA